Noncoding RNAs in osteosarcoma: Implications for drug resistance
- PMID: 33587978
- DOI: 10.1016/j.canlet.2021.02.007
Noncoding RNAs in osteosarcoma: Implications for drug resistance
Abstract
Osteosarcoma is the most frequent bone malignancy in children and adolescents. Despite advances of surgery and chemotherapy in osteosarcoma over the past decades, overall survival rates of osteosarcoma have reached a plateau. The development of multi-drug resistance (MDR) has become the main obstacle in improving chemotherapeutic effects in osteosarcoma treatment. Therefore, understanding detailed mechanisms of chemoresistance and developing novel therapeutic targets to overcome chemoresistance are crucial to improve the prognosis of osteosarcoma patients. Accumulating evidence has proved that multiple noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) play pivotal roles in osteosarcoma progression. Notably, a great number of ncRNAs are abnormally expressed and can regulate chemosensitivity through various mechanisms in osteosarcoma. In this review, we systematically summarize the roles of ncRNAs as well as the molecular mechanisms in modulating drug resistance of osteosarcoma and discuss the potential roles of ncRNAs as biomarkers and novel therapeutic targets for osteosarcoma.
Keywords: Circular RNA; Drug resistance; Long noncoding RNA; MicroRNA; Osteosarcoma.
Copyright © 2021 Elsevier B.V. All rights reserved.
Similar articles
-
Deciphering chemoresistance in osteosarcoma: Unveiling regulatory mechanisms and function through the lens of noncoding RNA.Drug Dev Res. 2024 Apr;85(2):e22167. doi: 10.1002/ddr.22167. Drug Dev Res. 2024. PMID: 38444106 Review.
-
Competitive endogenous network of circRNA, lncRNA, and miRNA in osteosarcoma chemoresistance.Eur J Med Res. 2023 Sep 16;28(1):354. doi: 10.1186/s40001-023-01309-x. Eur J Med Res. 2023. PMID: 37717007 Free PMC article. Review.
-
Targeting the Wnt/β-catenin cascade in osteosarcoma: The potential of ncRNAs as biomarkers and therapeutics.Pathol Res Pract. 2024 Jul;259:155346. doi: 10.1016/j.prp.2024.155346. Epub 2024 May 11. Pathol Res Pract. 2024. PMID: 38781762 Review.
-
Unraveling the impact of noncoding RNAs in osteosarcoma drug resistance: a review of mechanisms and therapeutic implications.Int J Surg. 2025 Feb 1;111(2):2112-2130. doi: 10.1097/JS9.0000000000002195. Int J Surg. 2025. PMID: 39784488 Review.
-
The emerging role of noncoding RNAs in colorectal cancer chemoresistance.Cell Oncol (Dordr). 2019 Dec;42(6):757-768. doi: 10.1007/s13402-019-00466-8. Epub 2019 Jul 29. Cell Oncol (Dordr). 2019. PMID: 31359293 Review.
Cited by
-
A tumor suppressor protein encoded by circKEAP1 inhibits osteosarcoma cell stemness and metastasis by promoting vimentin proteasome degradation and activating anti-tumor immunity.J Exp Clin Cancer Res. 2024 Feb 21;43(1):52. doi: 10.1186/s13046-024-02971-7. J Exp Clin Cancer Res. 2024. PMID: 38383479 Free PMC article.
-
Delivery of miRNAs Using Nanoparticles for the Treatment of Osteosarcoma.Int J Nanomedicine. 2024 Aug 22;19:8641-8660. doi: 10.2147/IJN.S471900. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39188861 Free PMC article. Review.
-
Intelligent structure prediction and visualization analysis of non-coding RNA in osteosarcoma research.Front Oncol. 2024 Mar 12;14:1255061. doi: 10.3389/fonc.2024.1255061. eCollection 2024. Front Oncol. 2024. PMID: 38532928 Free PMC article.
-
Non-Coding RNAs in Diagnostic Pathology of High-Grade Central Osteosarcoma.Diagnostics (Basel). 2025 May 28;15(11):1355. doi: 10.3390/diagnostics15111355. Diagnostics (Basel). 2025. PMID: 40506925 Free PMC article. Review.
-
Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.Front Immunol. 2022 Nov 15;13:1025532. doi: 10.3389/fimmu.2022.1025532. eCollection 2022. Front Immunol. 2022. PMID: 36457998 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous